Table 4 Adverse events during the study period
| Â | Quadruple treatment | Dual treatment |
|---|---|---|
Flushing | 0 | 1 (1.11%) |
Hypotension | 1 (1.11%) | 0 |
Fatigue | 1 (1.11%) | 1 (1.11%) |
Perspiration | 0 | 1 (1.11%) |
Poor appetite | 1 (1.11%) | 0 |
Cerebral infarctiona | 1 (1.11%) | 0 |
Headache | 0 | 1 (1.11%) |
Dizziness | 2 (2.22%) | 2 (2.22%) |
Palpitation | 0 | 2 (2.22%) |
Chest distress | 2 (2.22%) | 0 |
Gout | 0 | 0 |
Serum potassium decreased | 5 (5.56%) | 2 (2.22%) |
Serum sodium decreased | 0 | 0 |
Fasting blood glucose increased* | 9 (10.00%) | 2 (2.22%) |
Creatinine increased | 0 | 0 |
Blood urea increased | 0 | 0 |
Blood uric acid increased* | 21 (23.33%) | 1 (1.11%) |
Alanine aminotransferase increased | 2 (2.22%) | 3 (3.33%) |
Aspartate aminotransferase increased | 1 (1.11%) | 0 |
Total bilirubin increased | 0 | 1 (1.11%) |
Direct bilirubin increased | 0 | 0 |
Urinary protein increased | 0 | 0 |
QT interval prolongation | 0 | 0 |
QTc interval prolongation | 0 | 0 |
Total* | 46 (51.11%) | 17 (18.89%) |